Cost-effectiveness of ribociclib as initial treatment for premenopausal women with advanced breast cancer in Singapore.
Lydia Pui Yee LokeSoo-Chin LeeFiona PearceMohamed Ismail Abdul AzizMohamed Ismail Abdul AzizPublished in: Cancer reports (Hoboken, N.J.) (2020)
At its current price, adding ribociclib to endocrine therapy is unlikely to be cost-effective in Singapore for HR+, HER2- ABC. Results from this study are useful to inform future funding decisions for CDK4/6 inhibitors alongside other factors including clinical effectiveness, safety, and budget impact considerations.